Home LiteratureArticle Details
PMID: 2834736 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys.

Proceedings of the National Academy of Sciences of the United States of America ·Vol. 85 ·No. 9 ·1988-05-00 ·Pages 3203-7

Murray MG, Kuhn RJ, Arita M, Kawamura N, Nomoto A, Wimmer E

Abstract

Poliovirus exists as three stable serotypes (PV-1, PV-2, and PV-3). These viruses display three antigenic sites each, designated N-AgI, N-AgII, and N-AgIII. When mice are immunized with poliovirus, N-AgI is the major neutralization antigenic site for PV-3, whereas N-AgII and N-AgIII are immunodominant over N-AgI for PV-1. To study the relationship between structure and antigenicity, a hybrid virus was constructed in which N-AgI of PV-1 was replaced by N-AgI of PV-3. PV-3- and PV-1-specific antisera, including those elicited by PV-3 in primates, neutralized the hybrid virus. Injection of the hybrid virus into rabbits or into primates resulted in the production of antisera that neutralized both PV-1 and PV-3. The data show that sequence replacement at N-AgI of poliovirus is compatible with viral proliferation, an observation useful for the development of multivalent picornavirus vaccines.

MeSH Terms
Amino Acid Sequence Animals Antibodies, Viral/biosynthesis Base Sequence Haplorhini Mutation Oligonucleotides/analysis Poliovirus/immunology Poliovirus Vaccine, Inactivated Rabbits
Chemicals
Antibodies, Viral Oligonucleotides Poliovirus Vaccine, Inactivated
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Murray M G
Department of Microbiology, State University of New York, Stony Brook 11794-8621.
Kuhn R J
Arita M
Kawamura N
Nomoto A
Wimmer E
References (27)
27 references, click to expand
  1. DNA sequencing with chain-terminating inhibitors.
    Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 PMID: 271968
  2. Antigen chimaeras of poliovirus as potential new vaccines.
    Nature. 1988 Mar 3;332(6159):81-2 PMID: 2450279
  3. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome.
    Proc Natl Acad Sci U S A. 1981 Aug;78(8):4887-91 PMID: 6272282
  4. Location and primary structure of a major antigenic site for poliovirus neutralization.
    Nature. 1983 Feb 24;301(5902):674-9 PMID: 6186919
  5. Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies.
    J Virol. 1983 May;46(2):466-74 PMID: 6188863
  6. Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides.
    Nature. 1983 Aug 25-31;304(5928):699-703 PMID: 6310403
  7. The nucleotide sequence of poliovirus type 3 leon 12 a1b: comparison with poliovirus type 1.
    Nucleic Acids Res. 1983 Aug 25;11(16):5629-43 PMID: 6310508
  8. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome.
    Proc Natl Acad Sci U S A. 1982 Oct;79(19):5793-7 PMID: 6310545
  9. Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants.
    J Mol Biol. 1984 Apr 25;174(4):561-85 PMID: 6202874
  10. Systematic nomenclature of picornavirus proteins.
    J Virol. 1984 Jun;50(3):957-9 PMID: 6726891
  11. Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template.
    DNA. 1984 Dec;3(6):479-88 PMID: 6096101
  12. Rapid and efficient site-specific mutagenesis without phenotypic selection.
    Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92 PMID: 3881765
  13. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    J Gen Virol. 1985 May;66 ( Pt 5):1159-65 PMID: 2582084
  14. Structure of a human common cold virus and functional relationship to other picornaviruses.
    Nature. 1985 Sep 12-18;317(6033):145-53 PMID: 2993920
  15. Antigenic variation and resistance to neutralization in poliovirus type 1.
    Science. 1985 Sep 13;229(4718):1090-3 PMID: 2412292
  16. Three-dimensional structure of poliovirus at 2.9 A resolution.
    Science. 1985 Sep 27;229(4720):1358-65 PMID: 2994218
  17. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.
    J Virol. 1986 Jan;57(1):81-90 PMID: 2416957
  18. Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing.
    J Virol. 1986 Feb;57(2):515-25 PMID: 3003384
  19. Construction of poliovirus intertypic recombinants by use of cDNA.
    J Virol. 1986 Mar;57(3):1187-90 PMID: 3005620
  20. Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase.
    Proc Natl Acad Sci U S A. 1986 Apr;83(8):2330-4 PMID: 3010307
  21. Modulation of humoral response to a 12-amino-acid site on the poliovirus virion.
    J Virol. 1986 Oct;60(1):297-301 PMID: 3018295
  22. Genetic complementation among poliovirus mutants derived from an infectious cDNA clone.
    J Virol. 1986 Dec;60(3):1040-9 PMID: 3023656
  23. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984.
    JAMA. 1987 Mar 13;257(10):1335-40 PMID: 3029445
  24. Binding site of neutralizing monoclonal antibodies obtained after in vivo priming with purified VP1 of poliovirus type 1 is located between amino acid residues 93 and 104 of VP1.
    Virology. 1987 Mar;157(1):248-51 PMID: 2435056
  25. Identification and characterization of a continuous neutralization epitope (C3) present on type 1 poliovirus.
    Prog Med Virol. 1987;34:129-55 PMID: 2443945
  26. Construction of a "mutagenesis cartridge" for poliovirus genome-linked viral protein: isolation and characterization of viable and nonviable mutants.
    Proc Natl Acad Sci U S A. 1988 Jan;85(2):519-23 PMID: 2829191
  27. Primary structure, gene organization and polypeptide expression of poliovirus RNA.
    Nature. 1981 Jun 18;291(5816):547-53 PMID: 6264310
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
DOI
10.1073/pnas.85.9.3203
Published
1988-05-00
Pages
3203-7
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC280172
Subset
IM
Grants
NIAID NIH HHS · AI 15122 · United States
NCI NIH HHS · CA 28146 · United States
External Links
PubMed source DOI: 10.1073/pnas.85.9.3203 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2